Healthy Males Clinical Trial
Official title:
A Study in Healthy Subjects Designed to Evaluate the Pharmacokinetic Profile of Firibastat (QGC001) and Active Metabolites Following Administration of Firibastat (QGC001) Prototype Tablet Formulations
This is a single-centre, open-label, non-randomised, period fixed sequence study designed to
investigate the PK and safety of Firibastat (QGC001) modified release (MR) prototype tablet
formulations and compare this to a reference Firibastat (QGC001) immediate release (IR)
capsule formulation in healthy male subjects.
It is planned to enrol 12 subjects to receive single oral doses of investigational medicinal
product (IMP).
Subjects will be screened for eligibility to participate in the study up to 28 days before dosing and for each treatment period they will be admitted to the clinical unit on the evening prior to IMP administration (Day -1). On the morning of Day 1, subjects will receive IMP in the fasted state (or following a FDA standard high-fat breakfast, if applicable) and will remain on site until 48 h post-dose. Between the periods, an interim analysis and review of safety and PK data from dosed regimens will be performed in order to determine which Firibastat (QGC001) MR prototype tablet formulation and dose to administer in subsequent periods. A follow-up phone call will take place 7 to 10 days post-final dose to ensure the ongoing wellbeing of the subjects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04234594 -
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
|
Phase 1 | |
| Completed |
NCT01367561 -
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
|
Phase 1 | |
| Completed |
NCT00777543 -
Increasing Ferulic Acid Bioavailability in Bran
|
N/A | |
| Recruiting |
NCT04756635 -
Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity
|
N/A | |
| Completed |
NCT01848665 -
The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress
|
Phase 4 | |
| Completed |
NCT02156661 -
Oxytocin and Emotion Processing
|
Phase 1 | |
| Completed |
NCT05294198 -
Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males
|
N/A | |
| Completed |
NCT00839319 -
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
|
Phase 1/Phase 2 | |
| Completed |
NCT00842751 -
Oral T7 Oral Testosterone in Man
|
Phase 2 | |
| Completed |
NCT01847053 -
Bioavailability Study of Cinnamon in Healthy Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT01215292 -
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
|
Phase 1/Phase 2 | |
| Completed |
NCT00782392 -
Bioavailability and Dosing of a Monosaccharide Supplement in Adults
|
N/A | |
| Completed |
NCT05277597 -
Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota
|
N/A | |
| Completed |
NCT01032616 -
Uptake and Utilization of Amino Acids by Splanchnic Bed
|
Phase 1 | |
| Completed |
NCT01830335 -
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
|
Phase 4 | |
| Completed |
NCT00902512 -
Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations
|
Phase 4 | |
| Completed |
NCT00475371 -
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
|
Phase 1 | |
| Completed |
NCT01870102 -
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
|
Phase 1 |